Publications by authors named "Pierre Maisonblanche"

Claim this Profile
B
Baseline quantitative ECG parameters do not fully predict class 1 antiarrhythmic effect in Brugada patient: Drug-induced ECG changes in Brugada patients.
Pierre-Léo Laporte, Martino Vaglio, Isabelle Denjoy, Pierre Maison-Blanche, Philippe Maury

J Electrocardiol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Residual-attention deep learning model for atrial fibrillation detection from Holter recordings.
Md Moklesur Rahman, Massimo Walter Rivolta, Martino Vaglio, Pierre Maison-Blanche, Fabio Badilini

J Electrocardiol· May 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Automatized quantitative electrocardiography from digitized paper electrocardiograms: A new avenue for risk stratification in patients with Brugada syndrome.
Pierre-Léo Laporte, Martino Vaglio, Isabelle Denjoy, Pierre Maison-Blanche, Charlène Coquard

Arch Cardiovasc Dis· January 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A deep learning modular ECG approach for cardiologist assisted adjudication of atrial fibrillation and atrial flutter episodes.
Quentin Fleury, Rémi Dubois, Sylvain Christophle-Boulard, Fabrice Extramiana, Pierre Maison-Blanche

Heart Rhythm O2· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early warning of atrial fibrillation using deep learning.
Marino Gavidia, Hongling Zhu, Arthur N Montanari, Jesús Fuentes, Cheng Cheng

Patterns (N Y)· June 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Type 3 long QT syndrome: Is the effectiveness of treatment with beta-blockers population-specific?
Alexis Hermida, Jean-Baptiste Gourraud, Isabelle Denjoy, Véronique Fressart, Florence Kyndt

Heart Rhythm· March 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Computerized automated algorithm-based analyses of digitized paper ECGs in Brugada syndrome.
Fabrice Extramiana, Pierre-Léo Laporte, Martino Vaglio, Isabelle Denjoy, Pierre Maison-Blanche

J Electrocardiol· January 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Sex influences on ventricular repolarization duration in normal subjects and in type 1, 2 and 3 long QT syndrome patients: Different effect in acquired and congenital type 2 LQTS.
Fabrice Extramiana, Fabio Badilini, Isabelle Denjoy, Martino Vaglio, Cynthia L Green

J Electrocardiol· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
How a concentration-effect analysis of data from the eliglustat thorough electrocardiographic study was used to support dosing recommendations.
Jeremy N Ruskin, Catherine Ortemann-Renon, Jerome Msihid, Leorah Ross, Ana Cristina Puga

Mol Genet Metab· June 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of oral panobinostat plus subcutaneous bortezomib and oral dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma (PANORAMA 3): an open-label, randomised, phase 2 study.
Jacob P Laubach, Fredrik Schjesvold, Mário Mariz, Meletios A Dimopoulos, Ewa Lech-Maranda

Lancet Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Addendum to Letter to the Editor: Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Pramod K Mistry, Manisha Balwani, Hagit N Baris, Hadhami Ben Turkia, T Andrew Burrow

Blood Cells Mol Dis· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Eligibility of cardiac resynchronization therapy patients for subcutaneous implantable cardioverter defibrillators.
Ghassan Moubarak, Pierre Maison-Blanche, Olivier Thomas

J Electrocardiol· March 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial assessing the efficacy of S66913 in patients with paroxysmal atrial fibrillation.
A John Camm, Paul Dorian, Stefan H Hohnloser, Peter R Kowey, Benoît Tyl

Eur Heart J Cardiovasc Pharmacother· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety, efficacy, and authorization of eliglustat as a first-line therapy in Gaucher disease type 1.
Pramod K Mistry, Manisha Balwani, Hagit N Baris, Hadhami Ben Turkia, T Andrew Burrow

Blood Cells Mol Dis· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparison of automated interval measurements by widely used algorithms in digital electrocardiographs.
Paul Kligfield, Fabio Badilini, Isabelle Denjoy, Saeed Babaeizadeh, Elaine Clark

Am Heart J· June 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
QRS interval: What is it? How to measure it?
Fabrice Extramiana, Pierre Maison-Blanche

J Electrocardiol· May 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nonclinical cardiovascular safety of pitolisant: comparing International Conference on Harmonization S7B and Comprehensive in vitro Pro-arrhythmia Assay initiative studies.
Xavier Ligneau, Rashmi R Shah, Isabelle Berrebi-Bertrand, Gary R Mirams, Philippe Robert

Br J Pharmacol· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Management and monitoring recommendations for the use of eliglustat in adults with type 1 Gaucher disease in Europe.
Nadia Belmatoug, Maja Di Rocco, Cristina Fraga, Pilar Giraldo, Derralynn Hughes

Eur J Intern Med· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the Effects of CHF6001, an Inhaled PDE4 Inhibitor, on Cardiac Repolarization and Cardiac Arrhythmias in Healthy Volunteers.
Antonio Ferrari, Anna Compagnoni, Anne Nandeuil, Pierre Maison-Blanche

J Cardiovasc Pharmacol· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Can an early phase clinical pharmacology study replace a thorough QT study? Experience with a novel H3-receptor antagonist/inverse agonist.
Rashmi R Shah, Pierre Maison-Blanche, Philippe Robert, Emmanuel Denis, Thierry Duvauchelle

Eur J Clin Pharmacol· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Establishing assay sensitivity in QT studies: experience with the use of moxifloxacin in an early phase clinical pharmacology study and comparison with its effect in a thorough QT study.
Rashmi R Shah, Pierre Maison-Blanche, Thierry Duvauchelle, Philippe Robert, Emmanuel Denis

Eur J Clin Pharmacol· December 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Stroke and atrial fibrillation: where to go from here?
Fabrice Extramiana, Pierre Maison-Blanche

Stroke· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
An open-label study to investigate the cardiac safety profile of cabazitaxel in patients with advanced solid tumors.
Pierre Maison-Blanche, Shaker Dakhil, Ari Baron, Sylvie Rottey, Fred Millard

Cancer Chemother Pharmacol· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gene-specific effect of beta-adrenergic blockade on corrected QT interval in the long QT syndrome.
Fabrice Extramiana, Pierre Maison-Blanche, Isabelle Denjoy, Patrick De Jode, Anne Messali

Ann Noninvasive Electrocardiol· July 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled study to assess QTc interval prolongation of standard dose aflibercept in cancer patients treated with docetaxel.
Pierre Maison-Blanche, Jan B Vermorken, Tuncay Goksel, Jean-Pascal Machiels, Sanjiv Agarwala

J Cardiovasc Pharmacol· June 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis